Coley Doubles Toll-Like Receptor Patent Estate With Purchase Of 3M Program
This article was originally published in The Pink Sheet Daily
Executive Summary
$20 million investment also gains the TLR-focused firm a pipeline of small molecule candidates targeting TLR7 and TLR8, as well as a 10,000 compound library.
You may also be interested in...
Pfizer Strengthens Therapeutic Vaccine Position With Coley Purchase
Pharma giant gains control over Coley’s Toll-like receptor patent estate and next-generation vaccine adjuvants with $164 million acquisition.
Pfizer Strengthens Therapeutic Vaccine Position With Coley Purchase
Pharma giant gains control over Coley’s Toll-like receptor patent estate and next-generation vaccine adjuvants with $164 million acquisition.
Pfizer Picks Second TRL9 Candidate From Coley For Development In Oncology
Company will continue investigating compounds despite a recent setback with its Toll-like receptor program in lung cancer.